09/02/2026
Medicare's GLP-1 BRIDGE PROGRAM
Around 600,000 seniors signed up for GLP-1 weight-loss medications during the first two months of the newly launched federal Medicare Bridge program.
Announced by Centers for Medicare & Medicaid Services (CMS) Administrator Dr. Mehmet Oz, this temporary pilot program bypassed traditional restrictions to cap out-of-pocket costs for these highly sought-after treatments at just $50 a month.
Key Details of the Medicare Bridge ProgramLaunch Date: July 2026.Duration: Active through December 31, 2027.
Monthly Cost: $50 co-pay per covered prescription.
Covered Medications: Popular GLP-1s including Wegovy, Zepbound, and Foundayo.Manufacturer Partners: Developed through federal agreements with Novo Nordisk and Eli Lilly.
Eligibility CriteriaSeniors must obtain coverage through a Medicare Part D plan and meet one of the following health requirements:A Body Mass Index (BMI) of 35 or higher.A BMI over 30 combined with certain pre-existing conditions like high blood pressure, prediabetes, or a history of heart attack or stroke.
Why This MattersHistorically, federal law has explicitly banned Medicare Part D from covering prescription medications used strictly for weight loss. The Bridge program serves as an administrative workaround to treat obesity early. Officials project that expanding access will dramatically lower overall healthcare costs by preventing subsequent hospitalizations for chronic diseases.
If you are a Medicare beneficiary interested in this program, let me know if you would like me to find:The specific prior authorization forms required by CMS.Details on how this co-pay affects your standard Part D deductible.Guidelines on switching Part D plans to secure long-term coverage.
